Study Assessing QBS72S For Treating Brain Metastases

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Brain MetastasesBreast CancerLung CancerLeptomeningeal DiseaseLMD

Interventions

DRUG

QBS72S

QBS72S 18mg/m2 injection given intravenous once a month.

Trial Locations (1)

Stanford Cancer Institute, Palo Alto

All Listed Sponsors

collaborator

Quadriga Biosciences, Inc.

INDUSTRY

lead

Stanford University

OTHER